Display options
Cite
Beaud F, Pruijm M, Humbert A, et al. Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux. [Renal aspects of sodium glucose cotransporter 2 inhibitors]. Rev Med Suisse. 2015;11(463):488-92
Beaud, F., Pruijm, M., Humbert, A., Burnier, M., & Zanchi, A. (2015). Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux. [Renal aspects of sodium glucose cotransporter 2 inhibitors]. Revue medicale suisse, 11(463), 488-92.
Beaud, F, et al. "Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux." [Renal aspects of sodium glucose cotransporter 2 inhibitors]. Revue medicale suisse vol. 11,463 (2015): 488-92.
Beaud F, Pruijm M, Humbert A, Burnier M, Zanchi A. Les inhibiteurs du cotransporteur SGLT2 comme nouveau traitement du diabète: aspects rénaux. [Renal aspects of sodium glucose cotransporter 2 inhibitors]. Rev Med Suisse. 2015 Feb 25;11(463):488-92. French. PMID: 25898456.
Copy Download .nbib Format: NLM
Share it on

Rev Med Suisse. 2015 Feb 25;11(463):488-92.

[Renal aspects of sodium glucose cotransporter 2 inhibitors].

Revue medicale suisse

[Article in French]
F Beaud, M Pruijm, A Humbert, M Burnier, A Zanchi

PMID: 25898456

Abstract

It has been known for centuries that the kidneys play a role in glucose homeostasis, yet the underlying tubular mechanisms have only been recently identified by studying patients with familial glucosuria. These insights have lead to the commercialization of a novel class of oral antidiabetic agents named gliflozines. Gliflozines induce renal glucosuria by blocking the Na-glucose cotransporter SGLT2, localized in the proximal tubule, and allow a reduction of 0.5 to 1% of glycated hemoglobin. They also diminish proximal sodium reabsorption, and reduce the glomerular hyperfiltration that is often seen in the early stages of diabetes. Preliminary data suggest that they may decrease blood pressure and have renoprotective effects. This article provides an overview of the role of kidneys in glucose homeostasis and the renal effects of SGLT2-inhibitors.

Substances

MeSH terms

Publication Types